EUDA Health secures worldwide distribution rights for Chemokine supplement

EUDA Health (EUDA) announced that its wholly-owned subsidiary, EUDA Health, has secured exclusive worldwide distribution rights for a next-generation immune health supplement from Chemokine. EUDA and its subsidiaries will market and sell the Supplement under the brand name, Euda Helixe, initially in Singapore, Malaysia, and China before expanding it to other markets in the future. The addition of the Supplement will further reinforce EUDA’s wellness product portfolio as it drives the transformation of the health and wellness landscape in the region. The Supplement is an advanced formulation designed to modulate gene expression by activating beneficial genes while silencing harmful ones. Leveraging cutting-edge epigenetic technology, the Supplement enhances metabolism, boosts vitality, supports longevity, and is positioned as a foundational pillar in EUDA’s growing wellness product suite.